About AVEO

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AVEO is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 20.4 B 2.04474E+10 3,545 3545 0.0% 0 31 K 30567
IWC iShares Microcap ETF 858.7 M 8.58676E+08 1,430 1430 0.02% 0.0002 180 K 179554
IWM iShares Russell 2000 ETF 41.2 B 4.12382E+10 1,985 1985 0.0% 0 1.5 M 1508520
IWN iShares Russell 2000 Value ETF 8.5 B 8.54849E+09 1,351 1351 0.0% 0 274 K 273509
IWO iShares Russell 2000 Growth ETF 8.9 B 8.9462E+09 1,230 1230 0.0% 0 364 K 364367
IWV iShares Russell 3000 ETF 9.3 B 9.30666E+09 2,929 2929 0.0% 0 27 K 26598
URTY ProShares UltraPro Russell2000 90.2 M 9.0207E+07 1,996 1996 0.0% 8.52675E-06 3 K 2527
UWM ProShares Ultra Russell2000 162.4 M 1.62362E+08 1,996 1996 0.0% 1.47186E-05 5 K 5204